Seasun Biomaterials's MSI Diagnostic Kit, Selected as'Next Generation World-Class Product'

HOME Issue/Media News

News

Seasun Biomaterials's MSI Diagnostic Kit, Selected as'Next Generation World-Class Product'

운영자
Date 2021.01.26
Hit 17,602

Ministry of Trade, Industry and Energy-KOTRA, selected as a world-class product leap forward within the next 7 years

▲ Park Hee-kyung, CEO of SeaSun Biomaterials, who received the certificate of'the next-generation world-class product' (center).

SeaSun Biomaterials announced on the 22nd that the 'U-TOP MSI Detection Kit', a microsatellite instability test kit, was selected as the'next-generation world-class product'.

World-class products hosted by the Ministry of Trade, Industry and Energy and supervised by the Korea Trade-Investment Promotion Agency (KOTRA) are evaluated on demanding conditions for marketability and growth. It is certified as a world-class product.

SeaSun Biomaterials's 'U-TOP MSI Detection Kit' is a product that tests 'Microsatellite Instability (MSI)', a gene that reflects the accumulation of mutations that are the main cause of cancer. Approved for Class 3 and CE certified.

This product is the first diagnostic kit that uses a real-time PCR to quickly and easily diagnose and analyze MSI, replacing the existing tests that require cumbersome analysis procedures using expensive analysis equipment. Currently, the use of products is gradually increasing, mainly in large domestic hospitals, and overseas expansion is also being sought.

SeaSun Biomaterials plans to increase the marketability by expanding the indications of this product. It is currently being used as a screening test for colorectal cancer and gastric cancer, and recently, a clinical trial for endometrial and ovarian cancer has been successfully completed, so it applied for permission from the Ministry of Food and Drug Safety. It plans to add pancreatic cancer next year.

It is known that MSI-positive patients have a good therapeutic effect against immuno-cancer drugs. The U.S. Food and Drug Administration (FDA) approved that if the MSI test result was positive, the immune anticancer drug Kitruda could be prescribed regardless of carcinoma, and it has now established itself as a standard treatment method for a total of 16 carcinomas.

CEO Park Hee-kyung said, “Following the MSI products, we will develop more advanced technologies and products, and strive to enter the domestic and overseas markets.” “Starting with the selection of this next-generation world-class product, we will strive to strengthen our competitiveness. I will contribute to the development.”